Bausch + Lomb, which is listed on both the Toronto and New York stock exchanges, said full separation remains the goal, and that it continues to operate as its own entity. Bausch Health said it would ...

The acquisition strengthens Bausch + Lomb’s clinical-stage pipeline. Whitecap’s therapies are focused on glaucoma and geographic atrophy. Bausch + Lomb acquired Whitecap Biosciences ...

Bausch Health Companies Inc.’s years-long process of trying to separate its Bausch + Lomb Corp. eye-care business hit a roadblock Thursday when a potential sale to private equity fell through ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday, sending its ...

It provides range of vision beyond one focal point. Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release. Using intermediate ...

Jefferies analyst Glen Santangelo downgraded Bausch Health (BHC) to Hold from Buy with a price target of $8, down from $12, after the company ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Bullish option flow detected in Bausch Health (BHC) with 2,505 calls trading, 4x expected, and implied vol increasing over 13 points to 75.85%. Jan-26 10 calls and Mar-25 8 calls are the most ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and ...

His friend Henry Lomb invested his savings in Bausch's shop and in 1855 became his partner. Even with the loan, the business floundered until Bausch stumbled upon a piece of vulcanized rubber on a ...